Dear {{Account.Salutation}} {{Account.LastName}}
a child playing with toys

IT'S HARD TO TALK ABOUT MIGRAINE.
If you’ve never experienced one, you’ll
never understand the impact it can have.

 

Let’s give everyone with migraine a voice and turn private pain into collective change. With better understanding, people living with migraine can start to receive the support they need.

 

For more information on treatment options in migraine management click here

 

 

 

Kind Regards

{{userName}}

{{userEmailAddress}}

{{User.MobilePhone}}

References: 1. Jürgens TP, Schulte LH, May A. Migraine trait symptoms in migraine with and without aura. Neurology 2014;82:1416-1424. 2. Silberstein SD. Migraine Pathophysiology and its clinical implications. Cephalalgia, 2004, 24 (Suppl. 2), 2-7.
S4 Pasurta 70 mg/mL solution for injection in a pre-filled syringe: 54/7.3/0587. 70 mg erenumab in 1.0 mL (70 mg/mL) solution for injection. For full prescribing information, refer to the Professional Information approved by the South African Health Products Regulatory Authority.

Novartis South Africa (Pty) Ltd, Magwa View, Magwa Crescent West, Waterfall City, Jukskei View, Gauteng, 2090. Co. Reg. No. 1946/020671/07. Tel. No. +27 (0) 11 347 6600. To report an adverse event, email: patientsafety.sacg@novartis.com or report it directly through our website: www.novartis.com/report. Alternatively, call 0861 929 929. To report product quality complaints, email: qa.phzais@novartis.com. Alternatively, call 0861 929 929.

FA-11520856 Approval Date: 12/12/2025 Expiry Date: 12/12/2027
blue letters on a white background
a logo with a drop of water

You are receiving this email because you have been identified as a valuable Novartis HCP and we respect your privacy.

For more information on how we treat your personal information, please see our privacy notice

 

To manage your subscription or to unsubscribe from further Novartis communication, please click here